MMED Stock Forecast & Price Target

Minimed Group is favored because its stand-alone setup follows a turnaround from years of share loss and underinvestment, while remediation and stepped-up investment under Que Dallara have restored growth momentum. Its integrated AID stack, combining pumps, CGMs, smart pens and a pharmacy, should benefit from underpenetrated T1/T2 markets, with U.S. revenue at $240M, CGM attachment at 69%, and FY27 organic growth guided around 10.5%. Management also has multiple catalysts ahead, including Flex, Fit, Vivera and the next-gen sensor, while the company enters with $207M of cash, no debt, and a margin path toward 16% by FY27 and 20.8% by FY29E.

Minimed Group is burdened by a still-unresolved separation from Medtronic, with roughly 90% ownership and consolidated results creating a management overhang that can distort trading dynamics and delay a true independent re-rating. Its growth case also looks fragile because AID expansion is concentrated in the patch format, durable pumps are slower-growing and margin-disadvantaged, and new patient starts could be pressured by competitive headwinds, limited product traction, or delays to the planned summer 2027 FIT launch. Financially, the company faces additional margin and earnings pressure from remaining transition service agreements, royalty obligations to Blackstone, and any disruption to Abbott’s exclusive CGM supply relationship, all of which could slow profitability improvement.